CT REIT Declares Distribution for the Period of January 1, 2024 to January 31, 2024
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
TORONTO, Jan. 15, 2024 /CNW/ - CT Real Estate Investment Trust ("CT REIT") (TSX: CRT.UN) announced today that the trustees of CT REIT have declared a distribution for the period of January 1, 2024 to January 31, 2024 of $0.07485 per trust unit, payable February 15, 2024 to unitholders of record on January 31, 2024. This distribution, if annualized, would represent a rate of $0.89821 per annum.
About CT REIT
CT REIT is an unincorporated, closed-end real estate investment trust formed to own income-producing commercial properties located primarily in Canada. Its portfolio is comprised of over 370 properties totalling more than 30 million square feet of GLA, consisting primarily of net lease single-tenant retail properties located across Canada. Canadian Tire Corporation, Limited is CT REIT's most significant tenant. For more information, visit ctreit.com.
In line with their commitment to upholding the highest standards of transparency, below is the Adani Portfolio's Credit and Result compendium for financial year 2023-24.
The performance in FY24 and the past five years signify the strength and...
Linker Vision, a pioneer in AI technology, is proud to announce a collaboration with NVIDIA aimed at accelerating vision AI adoption across enterprise applications with large vision models (LVMs). Through this collaboration, Linker Vision is poised...
ConcertAI, the leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration with NVIDIA to advance a broad set of translational and clinical development solutions within the ConcertAI CARA AI platform....
Vention, the company behind the cloud-based Manufacturing Automation Platform (MAP), today announced a collaboration with NVIDIA to bring industrial automation technology to small and medium manufacturers by using NVIDIA AI and accelerated computing...
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
